Scholarlink

<p>Leadless pacemakers (LP) have emerged as a&#xa0;validated alternative to conventional transvenous systems, offering significant complication reduction by eliminating leads and device pockets. Current LP technologies include the Micra™ series (Medtronic, Minneapolis, MN, USA) and the modular Aveir™ system (Abbott Laboratories, Abbott Park, IL, USA), enabling the first fully leadless dual-chamber pacing. Clinical benefits are most evident in patients at high infection risk or with venous access limitations. Advances such as atrioventricular (AV)-synchronous pacing and long battery life have broadened indications, while maintaining stable device performance. Key challenges remain in end-of-life management and guideline integration. Future directions may involve combinations with subcutaneous implantable cardioverter–defibrillators (ICDs) or energy-harvesting technologies, further expanding therapeutic applications.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Kabellose Herzschrittmacher

  • 期刊论文

  • 发表日期：

    2025年10月30日

查看全文
  • Arian Sultan,
  • David Duncker,
  • Henning Jansen,
  • Micaela Ebert,
  • Victoria Johnson,
  • Till Althoff,
  • Tillmann Maurer,
  • Sascha Rolf,
  • Christian Heeger,
  • Heidi Estner,
  • Andreas Rillig,
  • Philipp Sommer,
  • Leon Iden,
  • K. R. Julian Chun,
  • Sonia Busch,
  • Roland Tilz,
  • Tillmann Dahme,
  • Daniel Steven

摘要

Leadless pacemakers (LP) have emerged as a validated alternative to conventional transvenous systems, offering significant complication reduction by eliminating leads and device pockets. Current LP technologies include the Micra™ series (Medtronic, Minneapolis, MN, USA) and the modular Aveir™ system (Abbott Laboratories, Abbott Park, IL, USA), enabling the first fully leadless dual-chamber pacing. Clinical benefits are most evident in patients at high infection risk or with venous access limitations. Advances such as atrioventricular (AV)-synchronous pacing and long battery life have broadened indications, while maintaining stable device performance. Key challenges remain in end-of-life management and guideline integration. Future directions may involve combinations with subcutaneous implantable cardioverter–defibrillators (ICDs) or energy-harvesting technologies, further expanding therapeutic applications.